KalVista Pharmaceuticals, Inc. (KALV)

KalVista Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is May - April.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	56.24	30.73	50.59	15.79	32.01
Short-Term Investments	93.14	135.47	198.34	51.93	68.81
Cash & Cash Equivalents	149.38	166.2	248.93	67.71	100.81
Cash Growth	-10.12%	-33.23%	267.62%	-32.83%	97.46%
Other Current Assets	22.95	27.45	15.34	20.98	14.74
Total Current Assets	172.33	193.65	264.26	88.7	115.55
Property, Plant & Equipment	10.77	10.04	7.55	3.66	2.41
Other Long-Term Assets	0.11	0.19	0.2	0.18	0.17
Total Long-Term Assets	10.88	10.23	7.75	3.83	2.59
Total Assets	183.2	203.88	272.01	92.53	118.13
Accounts Payable	4.82	3.64	1.98	1.68	2.86
Deferred Revenue	0	0	0	0	12.89
Other Current Liabilities	10.22	7.94	7.79	6.04	2.31
Total Current Liabilities	15.03	11.58	9.77	7.72	18.05
Long-Term Debt	7.15	7.21	5.05	1.06	0
Other Long-Term Liabilities	0	0	0	0	3.34
Total Long-Term Liabilities	7.15	7.21	5.05	1.06	3.34
Total Liabilities	22.18	18.79	14.82	8.78	21.39
Total Debt	7.15	7.21	5.05	1.06	0
Debt Growth	-0.92%	42.91%	377.39%	-	-
Retained Earnings	-343.08	-250.18	-167.84	-121.59	-92.48
Comprehensive Income	-3.06	-3.86	-1.43	-1.88	-1.93
Shareholders' Equity	161.03	185.09	257.19	83.75	96.74
Net Cash / Debt	142.23	158.99	243.88	66.66	100.81
Net Cash / Debt Growth	-10.54%	-34.81%	265.88%	-33.88%	98.54%
Net Cash Per Share	5.10	6.50	12.77	3.76	6.68
Working Capital	157.29	182.07	254.49	80.98	97.49
Book Value Per Share	5.77	7.56	13.47	4.72	6.42

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).